文献速递慢性肾脏病

CKD患者接受循证药物治疗的性别差异

Sex disparities in receiving evidence-based medications in patients with CKD.
PubMed 文献 · Nephrol Dial Transplant · 2026-06-19

本研究为GKPTN前瞻性国际队列的子研究,纳入4192例CKD患者(女性占40.9%),评估性别与接受循证药物(RASi、SGLT2i、利尿剂)的关系。调整年龄、地区、收缩压、BMI、心血管病、糖尿病、CKD病因及预后风险后,女性接受RASi(OR=0.75,95%CI 0.64-0.88;P<0.001)和SGLT2i(OR=0.79,95%CI 0.64-0.98;P=0.03)的 odds 显著低于男性,利尿剂无显著差异。性别与关键临床特征无显著交互作用。

要点

  • 女性CKD患者接受RASi的 odds 显著低于男性(OR=0.75)。
  • 女性接受SGLT2i的 odds 亦低于男性(OR=0.79),差异有统计学意义。
  • 利尿剂使用无显著性别差异,且差异在高风险亚组中一致。

核心结论

  • 女性CKD患者接受循证药物RASi和SGLT2i的可能性低于男性,且不受既定CKD风险因素影响。

研究设计与样本

  • 全球肾脏患者试验网络(GKPTN)前瞻性观察性国际CKD队列的子研究,共纳入4192例合格参与者,女性占40.9%。

主要发现

  • 调整年龄、地区、收缩压、BMI、心血管病、糖尿病、CKD病因和预后风险后,女性接受RASi的OR=0.75(95%CI 0.64-0.88;P<0.001),接受SGLT2i的OR=0.79(95%CI 0.64-0.98;P=0.03),均低于男性。
  • 利尿剂接受率无显著性别差异。
  • 性别与高龄、高KDIGO预后风险及合并症等关键临床特征无显著交互作用,差异在高风险亚组中保持一致。

临床怎么用

  • 临床中应关注CKD女性患者循证药物(RASi、SGLT2i)的处方不足,主动评估并纠正治疗差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND HYPOTHESIS: Chronic kidney disease (CKD) is a growing global health burden. While studies have demonstrated sex disparities in CKD prevalence and outcomes, evidence on sex-based differences in therapeutic management remains limited. This analysis aims to assess sex disparities in the receipt of evidence-based medications in a global CKD cohort. METHODS: This study is a sub-study of the Global Kidney Patient Trials Network (GKPTN), a prospective, observational, international cohort of CKD patients. The exposure of this study is biological sex, and the main outcomes are the receipt of evidence-based medications for CKD, including renin-angiotensin system inhibitors (RASi), sodium glucose co-transporter 2 inhibitor (SGLT2i) and diuretics. Adjusted multivariable logistic models were conducted to examine associations between sex and proportion of receiving medications, as well as the interactions between sex and other key clinical characteristics (advanced age, high KDIGO prognosis risk, and comorbid condition). RESULTS: A total of 4192 participants were eligible, and 40.9% were female. Females had lower odds of receiving RASi (OR = 0.75, 95% CI 0.64-0.88; P < 0.001) and SGLT2i (OR = 0.79, 95% CI 0.64-0.98; P = 0.03) compared to males, after adjusting for age, region, systolic blood pressure (SBP), body mass index (BMI), presence of cardiovascular disease and diabetes, CKD aetiology and prognosis risk, with no significant difference in the receipt of diuretics. There were no significant interactions between sex and any other key clinical characteristics, indicating that the disparities in the receipt of RASi and SGLT2i remained consistent across high-risk subgroups. CONCLUSION: Female patients with CKD are less likely to receive evidence-based medications than males, irrespective of established CKD risk factors. This difference highlights potential inequities in treatment globally which may result in outcome disparities.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Du R, Wallace H, Ha JT, et al. Sex disparities in receiving evidence-based medications in patients with CKD. Nephrol Dial Transplant. 2026. PMID: 42319802. doi:10.1093/ndt/gfag135

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。